Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of June 2026, with a report date of June 23, 2026. The document serves as a transaction notification detailing share purchases by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). GSK plc is a global biopharma company registered in England & Wales.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Ordinary Shares (GB00BN7SWP63): Purchased at a price of £19.3524 per share.
- American Depositary Shares (ADS) (US37733W2044): Purchased at a price of $50.6908 per ADS.
Material Changes and Transactions
The filing reports the following specific transactions executed by directors:
- Sir Jonathan Symonds (Non-Executive Chair): Purchased 1,550 Ordinary Shares on June 19, 2026, on the London Stock Exchange (XLON).
- Elizabeth (Liz) McKee Anderson (Independent Non-Executive Director): Purchased 789 ADS on June 22, 2026, on the New York Stock Exchange (XNYS).
- Charles Bancroft (Senior Independent Non-Executive Director): Purchased 1,855 ADS on June 22, 2026, on the New York Stock Exchange (XNYS).
- Dr Anne Beal (Independent Non-Executive Director): Purchased 745 ADS on June 22, 2026, on the New York Stock Exchange (XNYS).
- Dr Hal Dietz (Independent Non-Executive Director): Purchased 667 ADS on June 22, 2026, on the New York Stock Exchange (XNYS).
- Dr Jeannie Lee (Independent Non-Executive Director): Purchased 802 ADS on June 22, 2026, on the New York Stock Exchange (XNYS).
- Dr Vishal Sikka (Independent Non-Executive Director): Purchased 1,266 ADS on June 22, 2026, on the New York Stock Exchange (XNYS).
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory notification of insider trading activity.
Important Facts for Investors to Verify
- Verify the total aggregate volume of ADS purchases by the board of directors on June 22, 2026, which totaled 6,124 ADS.
- Confirm the exchange rate implications between the Ordinary Share price (£19.3524) and the ADS price ($50.6908) to assess valuation alignment.
- Note that all reported transactions were purchases, indicating insider confidence at the reported price points.
- Recognize that this filing contains no operational or financial performance data for the period.